Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
239.2 SEK | -0.25% |
|
-1.24% | +32.70% |
Jul. 03 | Sectra Launches Sectra One Cloud Service in Two Hospitals in Belgium | MT |
Jul. 03 | Two Belgian Hospitals Live with Sectra's Public Cloud Service for Medical Imaging Based on Microsoft Azure | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2027.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past twelve months, EPS forecast has been revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 87.62 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.70% | 4.4B | B- | ||
-4.71% | 29.66B | C | ||
+36.58% | 9.22B | C- | ||
-39.45% | 2.29B | C- | ||
-9.44% | 1.6B | - | C+ | |
-29.39% | 1.22B | B | ||
-43.35% | 970M | - | ||
-13.09% | 778M | C | ||
-48.40% | 718M | - | ||
-29.48% | 626M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SECT B Stock
- Ratings Sectra AB